Optimistic outlook for disease modifiers in osteoarthritis

Abstract

Any pharmaceutical company willing to invest heavily in osteoarthritis (OA) R&D has a good chance of identifying a disease modifying agent that will revolutionise OA therapy. This optimism was expressed at the 18th Meeting of the International League Against Rheumatism (ILAR), held earlier this month in Barcelona, Spain. It results from the increased understanding of how OA causes cartilage breakdown.